Several studies have reported that the neutrophil-to-lymphocyte ratio (NLR) at the initiation of anti–PD-1 blockade is potentially a marker of therapeutic outcomes in cancer patients; however, a definitive predictive biomarker in peripheral blood has not been found. This evidence concerns the gene PDCD1 and cancer.